The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries

Table 1

Relative distribution of U87MG, U87/EGFR, and U87/EGFRvIII glioma cells across the G1, S, and G2 phases of the cell cycle. Cells were treated for 48 h with Iressa, mechlorethamine (HN2), Iressa + HN2, ZRBA4, and ZR2003 in the absence or presence of 1 μM octreotide (OCT).

		U87MG	U87/EGFR	U87/EGFRvIII
Control	G1	73.0±3.4	80.0±2.2	83.3±0.2
	S	10.2±1.5	4.2±2.1	7.6±0.6
	G2	17.3±1.6	15.7±0.1	9.1±0.3
1 μM OCT	G1	77.2±0.8	82.7±2.9	82.7±1.2
	S	9.3±0.3	5.9±3.0	7.0±1.1
	G2	18.0±2.6	11.5±0.1	10.3±0.7
12.5 μM HN2	G1	51.5±7.8	20.7±2.7	55.0±0.2
	S	36.1±1.7	49.1±8.6	24.8±1.8
	G2	20.1±0.7	45.5±0.9	20.1±1.7
12.5 μM HN2 + 1 μM OCT	G1	18.7±2.2^∗	30.6±3.8	19.6±4.7^∗
	S	48.7±7.5	28.9±2.7	71.7±2.2^∗
	G2	59.5±2.3^∗	35.0±2.4	41.8±1.8^∗
12.5 μM Iressa	G1	49.6±5.7	63.6±0.4	58.2±2.3
	S	18.6±1.2	15.3±2.3	15.7±0.5
	G2	21.9±1.0	22.1±2.9	22.5±1.2
12.5 μM Iressa + 1 μM OCT	G1	53.1±4.7	58.3±2.5	66.3±2.8
	S	40.5±2.6^∗	22.7±2.1	24.7±2.3^∗
	G2	16.6±1.7^∗	16.0±1.7	13.6±1.4
12.5 μM (Iressa + HN2)	G1	25.7±6.4	32.0±3.4	32.5±9.3
	S	19.7±1.8	32.0±5.9	23.5±9.5
	G2	39.6±17.4	33.6±1.8	44.7±0.3
12.5 μM (Iressa + HN2) + 1 μM OCT	G1	23.5±3.9	39.5±3.8	34.9±3.9
	S	51.9±10.1	18.9±2.4	17.2±5.3
	G2	19.0±2.9	22.3±2.2	52.1±1.2^∗
12.5 μM ZRBA4	G1	12.2±0.3	15.6±0.2	60.5±0.3
	S	56.1±1.3	71.4±1.8	12.9±0.3
	G2	31.1±0.8	33.5±2.5	26.5±0.1
12.5 μM ZRBA4 + 1 μM OCT	G1	20.3±6.9	31.4±2.3	22.9±4.7
	S	59.3±4.0	39.0±4.1^∗	50.6±3.2^∗
	G2	23.7±3.4	28.8±2.1	28.3±0.8
12.5 μM ZR2003	G1	52.1±4.6	28.3±1.9	35.3±1.5
	S	26.3 ± 2.3	54.3±2.7	53.5±0.9
	G2	15.7 ± 2.0	12.7±0.2	13.9±1.7
12.5 μM ZR2003 + 1 μM OCT	G1	49.5±4.6	32.6±3.6	28.7±1.9
	S	25.7±1.6	57.8±0.9	57.1±0.5
	G2	19.3±1.5	12.5±1.3	12.1±2.6

*Shows statistical differences, within the same phase of the cell cycle, between drug alone and drug + OCT (𝑃<0.05).